2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Abstract Number: 76

Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome
Abstract Number: 77

Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study
Abstract Number: 78

Predictors of Outcome Following Tonsillectomy in Periodic Fever, Aphthous Stomatitis Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome
Abstract Number: 79

Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases
Abstract Number: 80

Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Abstract Number: 81

Preliminary Consensus Treatment Plans for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis: The Foundation for Capturing Treatment Responses in PFAPA from the CARRA PFAPA Subcommittee
Abstract Number: 82

Disease Burden and Social Impact of Chronic Nonbacterial Osteomyelitis on Affected Children and Young Adults
Abstract Number: 83

Feverprints: A Crowdsourcing Study of Temperature in Health and Disease
Abstract Number: 84

Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Abstract Number: 85

Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Abstract Number: 86

The myositis-specific autoantibody and myositis-associated autoantibody phenotypes in Japanese juvenile idiopathic inflammatory myopathies
Abstract Number: 87

Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
Abstract Number: 88

Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis
Abstract Number: 89

Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience
Abstract Number: 90

Risk of Serious Infections in Juvenile Dermatomyositis patients treated with biological response modifiers including rituximab and abatacept

« Previous Page
1
…
4
5
6
7
8
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].